- Home
- GAMB vs PSTX Comparison
GAMB vs PSTX Comparison
Compare GAMB & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAMB
- PSTX
- Stock Information
- Founded
- GAMB 2006
- PSTX 2014
- Country
- GAMB Jersey
- PSTX United States
- Employees
- GAMB N/A
- PSTX N/A
- Industry
- GAMB Services-Misc. Amusement & Recreation
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAMB Consumer Discretionary
- PSTX Health Care
- Exchange
- GAMB Nasdaq
- PSTX Nasdaq
- Market Cap
- GAMB 357.3M
- PSTX 249.1M
- IPO Year
- GAMB 2021
- PSTX 2020
- Fundamental
- Price
- GAMB $9.77
- PSTX $2.50
- Analyst Decision
- GAMB Strong Buy
- PSTX Strong Buy
- Analyst Count
- GAMB 4
- PSTX 2
- Target Price
- GAMB $13.25
- PSTX $15.00
- AVG Volume (30 Days)
- GAMB 91.9K
- PSTX 533.7K
- Earning Date
- GAMB 11-13-2024
- PSTX 11-07-2024
- Dividend Yield
- GAMB N/A
- PSTX N/A
- EPS Growth
- GAMB 445.61
- PSTX N/A
- EPS
- GAMB 0.67
- PSTX N/A
- Revenue
- GAMB $115,744,000.00
- PSTX $88,462,000.00
- Revenue This Year
- GAMB $17.13
- PSTX $36.53
- Revenue Next Year
- GAMB $11.30
- PSTX N/A
- P/E Ratio
- GAMB $14.65
- PSTX N/A
- Revenue Growth
- GAMB 23.58
- PSTX N/A
- 52 Week Low
- GAMB $7.52
- PSTX $1.83
- 52 Week High
- GAMB $13.88
- PSTX $4.27
- Technical
- Relative Strength Index (RSI)
- GAMB 45.32
- PSTX 38.80
- Support Level
- GAMB $9.85
- PSTX $2.41
- Resistance Level
- GAMB $10.06
- PSTX $2.61
- Average True Range (ATR)
- GAMB 0.19
- PSTX 0.12
- MACD
- GAMB -0.01
- PSTX -0.01
- Stochastic Oscillator
- GAMB 53.03
- PSTX 24.66
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.